A&S Biovecteurs closes $3.7 million financing; changes company name to Biovector Therapeutics.RAMONVILLE ST. AGNE AGNE Associated Grocers of New England , France--(BUSINESS WIRE)--Dec. 12, 1994--A&S Biovecteurs S.A., a privately held biopharmaceutical company, Monday announced the close of a $3.7 million financing. The company also announced a name change to Biovector Therapeutics S.A. The new name reflects the company's emphasis on developing pharmaceutical products based on its proprietary technology for delivery of drugs and therapeutic proteins, called supramolecular su·pra·mo·lec·u·lar adj. 1. Consisting of more than one molecule. 2. Of greater complexity than a molecule. biovectors. Participants in the financing included the company's previous venture capital investors Sofinnova and Finovelec, both of Paris, and Medical Science Partners of Boston. New investors included Atlas Venture Atlas Venture is an international early-stage venture capital firm that invests in communications, information technology, and life sciences companies. Atlas Venture has investing offices in Boston, London, Munich, and Paris, and its investments are evenly divided between the of Amsterdam/Paris and TVM TVM Time Value of Money (business, finance, economics) TVM Ticket Vending Machine TVM Thanks Very Much (logging abbreviation) TVM Transmission Voie Machine Techno Venture Management GmbH & Co. KG of Munich. The company raised $1.2 million in a previous round of financing in March 1994. "This successful financing demonstrates our investors' confidence in the versatility and power of supramolecular biovectors for entrapping and delivering a wide variety of therapeutic agents," said Mike Ullman, president directeur general of Biovector Therapeutics. "We plan to continue developing our biovector technology and to pursue product development through collaborations with pharmaceutical and biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. ." Supramolecular biovectors are minute particles that mimic the body's natural transport proteins -- low density lipoproteins Low density lipoproteins (LDL) A blood-plasma lipoprotein that is high in cholesterol and low in protein content and that carries cholesterol to cells and tissue; also called bad cholesterol. Mentioned in: C-Reactive Protein -- and can be used to entrap and deliver a variety of drugs and therapeutic proteins. Biovectors may be prepared in defined sizes ranging from 20 to several hundred nanometers, as required to meet drug delivery objectives. Biovectors consist of an inner solid core of cross-linked polysaccharide polysaccharide: see carbohydrate. polysaccharide Any of a large class of long-chain sugars composed of monosaccharides. Because the chains may be unbranched or branched and the monosaccharides may be of one, two, or occasionally more kinds, surrounded by an outer lipid membrane. The core functions as a reservoir for entrapped drugs, while the lipid membrane provides a biomimetic appearance that allows injected biovectors to circulate throughout the body for extended periods. By adjusting the ionic charge Noun 1. ionic charge - the charge on an ion is equal to a constant charge e multiplied by an integer from 1 to 15 constant - a number representing a quantity assumed to have a fixed value in a specified mathematical context; "the velocity of light is a constant" and concentration of the biovector core, a wide variety of drugs or proteins can be entrapped in the biovector. The company is also developing methods of incorporating ligands into the biovector's outer layer for drug delivery by specific metabolic pathways or to targeted cells. Biovector Therapeutics, formerly A&S Biovecteurs, develops biovector-based pharmaceutical products that improve drug efficacy and/or reduce their toxicity. Product development is presently focused on injectable and topical dosage forms of anti-cancer drugs, vaccines and therapeutic peptides/proteins. Founded in 1989, the company is located in Ramonville St. Agne, near Toulouse, France. CONTACT: Biovector Therapeutics S.A.
Mike Ullman, (33) 61 28 56 61
J. Kureczka Associates
Joan Kureczka, 415/821-2413
|
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion